How Does Pfizer Stock Stack Up Against Its Peers?
As of December 4, 2025, Pfizer‘s (PFE) stock returned 9% over the past year, outperforming MRK and BMY, but lagging LLY (23%) and JNJ (39%). A closer look reveals moderate profitability, with LTM operating margin (24.6%) and FCF margin (16.5%) trailing sector leaders like LLY (43% op margin). Its LTM revenue growth (3.9%) also lags LLY (36.8%). While PFE’s PE (14.7) suggests a reasonable valuation amidst a pharmaceutical industry accelerating innovation in AI and gene therapies, upside may be constrained by higher growth and innovation among peers.
- PFE’s 24.6% margin trails LLY’s 43.0%, reflecting PFE’s post-COVID sales decline versus LLY’s booming GLP-1 drug market leadership.
- PFE’s 3.9% revenue growth lags LLY’s GLP-1 boom & JNJ’s stable growth but surpasses MRK’s Keytruda LOE concerns & BMY’s Revlimid decline.
- PFE’s 9.2% stock gain, 14.7 PE, trails LLY’s GLP-1 surge & JNJ’s consistent growth, as PFE navigates post-COVID revenue declines.
Here’s how Pfizer stacks up across size, valuation, and profitability versus key peers.
| PFE | LLY | JNJ | MRK | BMY | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 146.1 | 910.9 | 487.6 | 251.7 | 105.8 |
| Revenue ($ Bil) | 62.8 | 53.3 | 92.1 | 64.2 | 48.0 |
| PE Ratio | 14.7 | 49.6 | 17.8 | 11.0 | 15.2 |
| LTM Revenue Growth | 3.9% | 36.8% | 5.1% | 1.7% | 1.3% |
| LTM Operating Margin | 24.6% | 43.0% | 26.2% | 34.9% | 23.8% |
| LTM FCF Margin | 16.5% | -0.1% | 20.3% | 20.3% | 31.9% |
| 12M Market Return | 9.2% | 23.2% | 38.7% | 3.2% | -6.6% |
For more details on Pfizer, read Buy or Sell PFE Stock. Below we compare PFE’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 3.9% | 6.8% | -41.1% | 24.5% |
| LLY | 36.8% | 32.0% | 19.6% | 0.8% |
| JNJ | 5.1% | 4.3% | 6.5% | 1.6% |
| MRK | 1.7% | 6.7% | 1.4% | 21.7% |
| BMY | 1.3% | 7.3% | -2.5% | -0.5% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 24.6% | 23.3% | 7.1% | 36.7% |
| LLY | 43.0% | 38.9% | 31.6% | 30.3% |
| JNJ | 26.2% | 24.9% | 27.5% | 26.3% |
| MRK | 34.9% | 31.5% | 4.9% | 30.8% |
| BMY | 23.8% | 12.2% | 18.2% | 19.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 14.7 | 18.7 | 76.7 | 9.2 |
| LLY | 49.6 | 65.7 | 100.1 | 52.8 |
| JNJ | 17.8 | 24.8 | 11.3 | 25.8 |
| MRK | 11.0 | 14.7 | 757.8 | 19.3 |
| BMY | 15.2 | -12.8 | 13.2 | 24.2 |
Still not sure about PFE stock? Consider portfolio approach.
A Multi Asset Portfolio Gives You Safer Smarter Growth
Individual stocks can soar or tank but multi asset exposure steadies the ride. A spread out portfolio captures upside while limiting the damage from any one market.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices